SynTra

Challenge

Cell and gene therapies hold great potential, but their impact is still constrained by the high cost and complexity of vector manufacturing. Viral vector production, in particular, remains expensive, difficult to scale, and too inefficient to support broad access to treatment. As a result, the promise of individualized therapies, such as TCR-treatments, remains limited by current manufacturing bottlenecks.

Solution

SynTra addresses this challenge by developing a fully synthetic, automated production process for tailor-made DNA vectors, designed to meet the unique needs of each individual therapy. By shifting away from viral vectors toward the Sleeping Beauty transposon system — a proven, non-viral approach for stable gene delivery — SynTra dramatically simplifies the manufacturing workflow. The result is a flexible platform capable of producing patient-specific vectors at a fraction of today’s cost and complexity.

Looking for

• Co-development partners
• Pilot partner
• Investors

Technology

SynTra is also available as technology asset.

News and background